Fate Therapeutics, Inc.
FATEDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ProTmune | Phase 2 | Hematologic Malignancies | - | - |
Lupus Nephritis
1 drug in this indication
treatment-resistant autoimmune disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Fate Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Fate Therapeutics, Inc.'s (FATE) pipeline across Phase 2. Its lead program is ProTmune (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Fate Therapeutics, Inc.'s next FDA catalyst?→
Fate Therapeutics, Inc.'s (FATE) next tracked catalyst is a Earnings expected November 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track FATE biotech catalysts?→
Add FATE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Fate Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.